Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Merlin Nexus

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 8
Average round size
info
The average size of a deal this fund participated in
$45M
Portfolio companies 7
Rounds per year 0.40
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Exits 6
Key employees 1

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Biopharma
  • Pharmaceutical
Summary

Merlin Nexus appeared to be the VC, which was created in 2001. The venture was found in North America in United States. The leading representative office of defined VC is situated in the New York.

We also calculated 1 valuable employee in our database.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Adaptimmune, Stem Cell Therapeutics, Zymeworks. Among the most popular fund investment industries, there are Biotechnology, Health Care.

The fund is constantly included in less than 2 deals per year. Opposing the other organizations, this Merlin Nexus works on 71 percentage points more the average amount of lead investments. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2017. The important activity for fund was in 2013.

The typical case for the fund is to invest in rounds with 7-8 participants. Despite the Merlin Nexus, startups are often financed by Warburg Pincus, Vector Fund Management, Mayfield Fund. The meaningful sponsors for the fund in investment in the same round are venBio Partners, Ridgeback Capital, New Enterprise Associates. In the next rounds fund is usually obtained by Eight Roads Ventures, Bridge Bank.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Merlin Nexus:
Typical Co-investors
Merlin Nexus is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Merlin Nexus:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Association of Otolaryngology Pennsylvania, Pittsburgh, United States
Black Green Capital England, London, United Kingdom
Bluehill California, San Francisco, United States
Cardinal Partners New Jersey, Princeton, United States
Fuyo General Lease Chiyoda, Japan
Greenfield Partners Israel, Tel Aviv, Tel Aviv District
K50 Ventures New York, New York, United States
Titan Capital Gurgaon, Haryana, India
Urrshila Kerkar -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Zymeworks

Biotechnology
Medical
Therapeutics
$61M08 Jan 2016 Vancouver, British Columbia, Canada

Adaptimmune

Biopharma
Biotechnology
Health Care
Medical
$104M25 Sep 2014 United Kingdom, England, United Kingdom

Stem Cell Therapeutics

Biopharma
Biotechnology
Therapeutics
$33M16 Dec 2013 Old Toronto, Ontario, Canada

WaferGen Biosystems

Biotechnology
Genetics
Life Science
Pharmaceutical
$30M31 May 2011 Fremont, California, United States

Sunesis Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$43M07 Apr 2009 South San Francisco, California, United States

Micromet

Biotechnology
Pharmaceutical
Therapeutics
$40M03 Oct 2008 Maryland, United States

Xencor

Biotechnology
Health Care
Therapeutics
$15M25 Oct 2007 El Monte, California, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Merlin Nexus?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: